<?xml version='1.0' encoding='UTF-8' ?><Trials_downloaded_from_ICTRP>
  <Trial>
    <TrialID>CTRI/2009/091/000527</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the safety and efficacy of 2 mg and 4 mg of ZYH1 compared to Pioglitazone 45 mg in dyslipidemia with type 2 diabetes mellitus.
Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS V).</Public_title>
    <Scientific_title>A multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of ZYH1 compared to Pioglitazone 45mg in dyslipidemia with  type 2 diabetes mellitus. - ZYH1.08.001.01.1 PROT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>09-09-2009</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=732                                                                                                                                                                                                </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>27-07-2009</Date_enrollement>
    <Target_size>122</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Randomized, Parallel Group, Placebo Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Participant, Investigator and Outcome Assessor Blinded</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>DrRHJani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Zydus Cadila House Plot no.360, TPS 5, Service road, Vile Parle (East)</Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>91-22-26186057</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcrae Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1: 2mg or 4mg once daily (OD)Oral&lt;br&gt;&lt;br&gt;Control Intervention1: Pioglitazone: 45mg OD&lt;br&gt;Oral&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary Efficacy&lt;br&gt;TG &lt;br&gt;Timepoint: Time frame 12 and 24 weeks &lt;br&gt;</Primary_outcome>
    <Secondary_outcome>Secondary Efficacy :&lt;br&gt;LDL,VLDL,HDL,Total cholesterol,Apo(a), Apo B,HbA1c,Fasting plasma glucose(FPG),C-peptide test and fasting insulin  for HOMA beta and HOMA IR,&lt;br&gt;hs-CRP,Post prandial triglyceride (PPTG) at selected centres&lt;br&gt;Timepoint: Time frame 12 and 24 weeks &lt;br&gt;</Secondary_outcome>
    <Secondary_ID>ZYH1.08.001.01.1.PROT+1 Amendment</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2009/091/000533</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the safety and efficacy of 2mg and 4mg of ZYH1 compared to placebo in hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VI)].</Public_title>
    <Scientific_title>A multi-centric, prospective, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of ZYH1 compared to placebo in hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>28-08-2009</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=736                                                                                                                                                                                                </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>10-08-2009</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Randomized, Parallel Group, Placebo Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Participant and Investigator Blinded</Study_design>
    <Countries>India;India</Countries>
    <Contact_Firstname>DrRHJani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Zydus Cadila House
Plot no.360, TPS 5, Service road,Vile Parle (East) </Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>91-22-26186057</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1 2mg &amp;amp; 4mg: once orally in the morning before breakfast, for 12 weeks.&lt;br&gt;Control Intervention1: Placebo: once orally in the morning before breakfast, for 12 weeks.&lt;br&gt;</Intervention>
    <Primary_outcome>Primary Efficacy : TG &lt;br&gt;Timepoint: Time frame 6 and 12 weeks &lt;br&gt;</Primary_outcome>
    <Secondary_outcome>Secondary Efficacy:1)LDL,2)VLDL,3)HDL, 4)Total cholesterol,5)Non HDL-C,6)Apo (a),7)Apo B,8)hs-CRP&lt;br&gt;Timepoint: Time frame 6 and 12 weeks &lt;br&gt;</Secondary_outcome>
    <Secondary_ID>ZYH1.09.002.01.1.PROT+1 Amendment</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2010/091/000107</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the effects of ZYH1 in patients with high triglyceride levels in HIV associated lipodystrophy. .[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VII)].</Public_title>
    <Scientific_title>A prospective, multi-centric, open-label, single arm study to evaluate the safety and efficacy of 4mg of ZYH1 in hypertriglyceridemia in HIV associated lipodystrophy - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>09-09-2010</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1322                                                                                                                                                                                               </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>21-08-2010</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Single Arm Trial&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Open Label</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>Dr R H Jani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Zydus Cadila House,2nd Floor Plot No. 360, TPS 5, Service road, Vile Parle (East) </Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>91-22-26186052</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1: Dose -4mg&lt;br&gt;Frequency-Once daily&lt;br&gt;Route-Oral&lt;br&gt;Control Intervention1: NA: NA&lt;br&gt;</Intervention>
    <Primary_outcome>TriglyceridesTimepoint: At 6 weeks and 12 weeks</Primary_outcome>
    <Secondary_outcome>Low density lipoprotein (LDL), &lt;br/ &gt;&lt;br&gt;Very low density lipoprotein (VLDL) High density lipoprotein (HDL)  &lt;br/ &gt;&lt;br&gt;Total cholesterol  &lt;br/ &gt;&lt;br&gt;Non HDL Cholesterol (Measured value) Apo(a)&amp; Apo B  &lt;br/ &gt;&lt;br&gt;Fasting insulin and C-peptide for HOMA beta and IR.Timepoint: At 6 weeks and 12 weeks</Secondary_outcome>
    <Secondary_ID>ZYH1.09.003.01.PROT,Version 1.0 dated 09/03/2009</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2010/091/000108</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the effects of 4 mg ZYH1 in patients with Non alcoholic steatohepatitis (NASH)..[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VIII)].</Public_title>
    <Scientific_title>A prospective, multi-centric, open-label, single arm study to evaluate the safety and efficacy of 4mg of ZYH1 in Non-alcoholic steatohepatitis (NASH). - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>22-07-2010</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1323                                                                                                                                                                                               </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>26-07-2010</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Single Arm Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Open Label</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>Dr RH Jani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Plot No. 360, TPS 5, Service Road, Vile Parle (East). </Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>26186057</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1: Dose-4mg &lt;br&gt;Frequency-once daily (OD), &lt;br&gt;Route-Oral&lt;br&gt;Control Intervention1: NIL: NIL&lt;br&gt;</Intervention>
    <Primary_outcome>Percentage decrease in ALT from baselineTimepoint: at 6 weeks and 12 weeks</Primary_outcome>
    <Secondary_outcome>C-peptide test for HOMA beta and HOMA IR&lt;br&gt;Timepoint: at 6 weeks and 12 weeks;Sustained reduction in ALT level.Timepoint: at 6 weeks and 12 weeks;TriglycerideTimepoint: at 6 weeks and 12 weeks</Secondary_outcome>
    <Secondary_ID>ZYH1.09.004.01.PROT,Version 1.0,dated 20/03/2009</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2010/091/000164</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the effects of ZYH1 and Fenofibrate in patients with high lipid levels.(Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS I).</Public_title>
    <Scientific_title>A 12 week, randomized, double blind parallel group prospective dose ranging study of ZYH1 with an open fenofibrate arm to evaluate the efficacy on dyslipidemia in patients without diabetes. - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>09-03-2010</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1377                                                                                                                                                                                               </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>08-08-2006</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Participant and Investigator Blinded</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>Dr RHJani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Cadila Healthcare limited, Zydus Cadila House Plot No. 360, TPS 5, Service Road, Vile Parle (East)</Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>91-22-26186052</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1 0.5mg, 1mg, 2mg and 4mg: one tablet once daily of either 0.5mg, 1mg, 2mg or 4mg in the morning for the entire duration of the study i.e. for 12 weeks.&lt;br&gt;Control Intervention1: Fenofibrate 160 mg: Frequency- once daily &lt;br&gt;Dosage-160mg&lt;br&gt;Route-Oral&lt;br&gt;</Intervention>
    <Primary_outcome>Primary efficacy endpoints: 1.Triglyceride 2.Low density Lipoproteins ( LDL) cholesterol, 3.Very low density lipoprotein (VLDL) cholesterol, 4.HDL cholesterol and 5.Fasting Glucose.Timepoint: From baseline, visit 2(Week 0)to visit 8 (Week 12)</Primary_outcome>
    <Secondary_outcome>Secondary efficacy endpoints: &lt;br/ &gt;&lt;br&gt;1.HbA1C, &lt;br/ &gt;&lt;br&gt;2.Insulin and &lt;br/ &gt;&lt;br&gt;3.C-Reactive protein(CRP) &lt;br/ &gt;&lt;br&gt;Timepoint: From baseline, visit 2(Week 0)to visit 8 (Week 12)</Secondary_outcome>
    <Secondary_ID>2001 Ver.01</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2010/091/000165</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the effects of two drugs,ZYH1 and Rosiglitazone in diabetic patients with high lipid levels.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS II)]</Public_title>
    <Scientific_title>A 12 week, randomised, double blind parallel group prospective dose ranging study of ZYH1 with an open Rosiglitazone arm to evaluate the efficacy on dyslipidemia in patients with diabetes - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>09-03-2010</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1378                                                                                                                                                                                               </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>02-11-2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>Dr RH Jani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Zydus Cadila House Plot No. 360, TPS 5, Service Road, Vile Parle (East)</Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>91-22-26186052</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1 0.5mg, 1mg, 2mg and 4mg: one tablet once daily of either 0.5mg, 1mg, 2mg or 4mg in the morning for the entire duration of the study i.e. for 12 weeks&lt;br&gt;Control Intervention1: Rosiglitazone 8/16 mg: one tablet once daily in the morning for the entire duration of the study i.e. for 12 weeks&lt;br&gt;</Intervention>
    <Primary_outcome>Primary efficacy endpoints: 1.Triglyceride 2.Low density Lipoproteins ( LDL) cholesterol, 3.Very low density lipoprotein (VLDL) cholesterol, 4.HDL cholesterol and 5.Fasting Glucose.Timepoint: From baseline, visit 2(Week 0)to visit 8 (Week 12)</Primary_outcome>
    <Secondary_outcome>Secondary efficacy endpoints: 1.HbA1C, 2.Insulin and 3.C-Reactive protein(CRP)Timepoint: From baseline, visit 2(Week 0)to visit 8 (Week 12)</Secondary_outcome>
    <Secondary_ID>2002 Ver.01</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2010/091/000166</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A clinical trial to study the effects of two drugs, ZYH1 and Pioglitazone in diabetic patients with high lipid levels.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS III)].</Public_title>
    <Scientific_title>A 12 week, randomised, double blind parallel group prospective dose ranging study of ZYH1 with an open Pioglitazone arm to evaluate the efficacy on dyslipidemia in patients with diabetes. - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>09-03-2010</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1379                                                                                                                                                                                               </web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>17-11-2006</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>Dr RHJani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Cadila Healthcare Limited, Zydus Cadila House Plot No. 360, TPS 5, Service Road, Vile Parle (East)</Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>91-22-26186052</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: ZYH1 0.5mg, 1mg, 2mg and 4mg: one tablet once daily of either 0.5mg, 1mg, 2mg or 4mg in the morning for the entire duration of the study i.e. for 12 weeks.&lt;br&gt;Control Intervention1: Pioglitazone (45 mg daily): one tablet once daily in the morning for the entire duration of the study i.e. for 12 weeks&lt;br&gt;</Intervention>
    <Primary_outcome>Primary efficacy endpoints: 1.Triglyceride 2.Low density Lipoproteins ( LDL) cholesterol, 3.Very low density lipoprotein (VLDL) cholesterol, 4.HDL cholesterol and 5.Fasting Glucose.Timepoint: From baseline, visit 2(Week 0)to visit 8 (Week 12)</Primary_outcome>
    <Secondary_outcome>Secondary efficacy endpoints: 1.HbA1C, 2.Insulin and 3.C-Reactive protein(CRP)Timepoint: From baseline, visit 2(Week 0)to visit 8 (Week 12)</Secondary_outcome>
    <Secondary_ID>2003 Ver.02</Secondary_ID>
    <Source_Support>Cadila Healthcare Limited</Source_Support>
  </Trial>
  <Trial>
    <TrialID>CTRI/2013/06/003754</TrialID>
    <Last_Refreshed_on>20 July 2014</Last_Refreshed_on>
    <Public_title>A phase IV clinical study to evaluate the safety and efficacy of Saroglitazar (ZYH1) as compared to fenofibrate in patients with dyslipidemia.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS X)].</Public_title>
    <Scientific_title>_??A multicentric,prospective, randomized, open label Phase IV clinical study to evaluate the safety and efficacy of Saroglitazar (ZYH1) as compared to fenofibrate in patients with dyslipidemia._?? - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Cadila Healthcare Limited</Primary_sponsor>
    <Date_registration>14-06-2013</Date_registration>
    <Export_date>8/5/2014 5:26:46 AM</Export_date>
    <Source_Register>CTRI</Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=6705                                                                                                                                                                                               </web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender />
    <Date_enrollement>20-08-2013</Date_enrollement>
    <Target_size>1010</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Randomized, Parallel Group, Multiple Arm Trial&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label</Study_design>
    <Countries>India</Countries>
    <Contact_Firstname>Dr R H Jani</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Zydus Cadila House Plot No. 360, TPS 5, Service Road, Vile Parle (E) Mumbai MAHARASHTRA 400 057 India </Contact_Address>
    <Contact_Email>rhjani@zyduscadila.com</Contact_Email>
    <Contact_Tel>26186052</Contact_Tel>
    <Contact_Affiliation>Cadila Healthcare Limited</Contact_Affiliation>
    <Intervention>Intervention1: Fenofibrate: Route-Oral Frequency -Once daily Duration -06 Months Dosage :-Fenofibrate 160 Mg&lt;br&gt;Control Intervention1: Saroglitazar 2 Mg and 4 Mg: Route-Oral&lt;br&gt;Frequency -Once daily &lt;br&gt;Duration -06 Months &lt;br&gt;Dosage :-Saroglitazar 2 Mg 0r 4 Mg&lt;br&gt;</Intervention>
    <Primary_outcome>To compare the percentage change in triglyceride (TG) levels in 2 and 4 mg of Saroglitazar as compared to fenofibrateTimepoint: 6 weeks, 12 weeks and 24 weeks</Primary_outcome>
    <Secondary_outcome>1.To compare the percentage change in lipid parameters &lt;br/ &gt;&lt;br&gt;a.LDL,  &lt;br/ &gt;&lt;br&gt;b.VLDL, &lt;br/ &gt;&lt;br&gt;c.HDL-C,  &lt;br/ &gt;&lt;br&gt;d.Total cholesterol &lt;br/ &gt;&lt;br&gt;e.Non HDL cholesterol,  &lt;br/ &gt;&lt;br&gt;f.Apo A1  &lt;br/ &gt;&lt;br&gt;g.Apo B. &lt;br/ &gt;&lt;br&gt;2.To compare the percentage change in hs-CRP, an inflammatory marker of atherosclerosisTimepoint: 6 weeks, 12 weeks and 24 weeks</Secondary_outcome>
    <Secondary_ID>ZYH1.12.001.01.PROT, Version 1.0, Date 8 Nov 2012</Secondary_ID>
    <Source_Support>NA</Source_Support>
  </Trial>
</Trials_downloaded_from_ICTRP>